The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
DM2000 - fyi both appear be in Q1 so anytime I guess/hope :)
NXP002 - Inhaled therapy for Fibrotic Diseases
The priority of the Group remains the development of an inhaled therapy for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a serious lung disease, with its lead asset, NXP002.
Pre-clinical development activities were prioritised to evaluate the benefits of NXP002 alone and in combination with standard of care for the treatment of IPF. Results of this study are expected in the first quarter of 2021.
NXP004
NXP004 uses Nuformix proprietary technology applied to the active drug of a multi-billion-dollar product currently marketed for oncology indications. Despite the commercial success of the marketed product, side-effects pose a significant challenge to its existing use and extension into new indications, that could also benefit from its mechanism of action. We are currently evaluating new IP that could overcome some of the challenges posed by the originator's formulation.
Additionally, in August, the Group reported results from a pre-clinical pilot study evaluating the anti-fibrotic and anti-inflammatory effects of NXP004 against standard of care, a therapeutic area not currently exploited by the originator of the drug. We will confirm next steps in Q1 2021.
Still a waiting game but at least NFX have now put together a strong team plus a new broker. It does look like things are progressing. Getting the broker in place is essential for any deals, this is key and another piece of the jigsaw puzzle added.
Q1 it is then
It will be interesting to see how many ticks we have from said Fundraising Highlights when year end results drop!
The Net Placing Proceeds will be used to ‘accelerate’ business development with focus on the following key areas:
Update required please - Strengthen Group data packages for treating the effects of Covid-19
Update required please - Maximise opportunities for development pipeline especially lead asset, NXP002
Great signing - Recruit a CEO with responsibility for delivering the Group's strategy
Great signing - Augment and strengthen the Board with additional Non-Executive expertise
2 out of 4 ticks so far. Lets see what they have up there sleeve.